Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP

An off-the-shelf neoantigen boosting vaccine comprised of a modified Vaccinia virus Ankara (MVA) encoding tumor-specific neoantigens (TSNAs) derived from the same as of yet undisclosed frameshift peptides (FSPs) targeted by the priming vaccine, great ape adenoviral tumor-specific neoantigen priming vaccine GAd-209-FSP, with potential immunostimulatory and antineoplastic activities. Following intramuscular administration of the priming vaccine GAd-209-FSP, the booster MVA tumor-specific neoantigen boosting vaccine MVA-209-FSP may serve to further expand and improve the phenotyping of antigen-specific T-cells targeted to the tumor cells expressing the TSNAs.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Modified Vaccinia Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Modified Vaccinia Virus Ankara Tumor-specific Neoantigen Boosting Vaccine MVA-209-FSP
Code name:MVA-209-FSP
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search